XW143C8
Transfusion Central Vein to New Technology Group 8 with Omidubicel, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 1 Transfusion |
| Body Part | 4 Central Vein |
| Approach | 3 Percutaneous |
| Device | C Omidubicel |
| Qualifier | 8 New Technology Group 8 |
Operation Definition
Putting in blood or blood products
Procedure Overview
This family applies specifically to putting blood or blood products into a patient using a New Technology-designated product, distinguishing it from routine transfusions of standard blood components. It exists because certain newer blood-derived products, engineered or processed differently from conventional units, are tracked separately to monitor their use and outcomes.
A patient receiving this kind of transfusion is usually being treated for a condition where standard blood products have proven insufficient, such as certain bleeding disorders or infections, and the care team has opted for a product with novel approval status.
Anatomy & Axis Detail
Central Vein
When a New Technology transfusion product is delivered through a central vein, such as the superior vena cava, subclavian, or internal jugular approach to a central line, this code reflects that the therapy required central venous access rather than a peripheral limb vein. Central administration is typically chosen for products that are more concentrated, require rapid systemic distribution, or are irritating to smaller peripheral vessels, and it is also used when a patient already has a central line in place for other care. Because central venous catheterization itself carries risks like pneumothorax or catheter-related infection, documentation should confirm both the venous access site and the specific novel product transfused. Coding must distinguish this central-vein pathway from the peripheral-vein version of the same New Technology substance to reflect the different access route and associated risk profile.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Omidubicel
Omidubicel denotes administration of an ex vivo expanded, allogeneic umbilical cord blood-derived stem cell product used to support hematopoietic recovery after myeloablative conditioning in blood cancer patients undergoing transplant. Unlike the autologous gene therapies elsewhere in this list, it uses donor-derived cells without genetic modification, aiming to shorten time to neutrophil engraftment and reduce infection risk during transplant.
Qualifier: New Technology Group 8
Group 8 identifies technologies added to the New Technology section for the 2021-2022 update cycle, tying a given code to that specific approval year. The underlying substance, device, or technique is defined by the other six axis positions, not by the group number itself. Because group numbers simply track chronology, Group 8 differs from Group 7 and Group 9 only in when CMS granted the technology separate recognition.
Coding & Documentation
The documentation needs to specify the exact blood product given, since this family is tied to specific New Technology-approved products rather than blood transfusion in general. Coders should confirm the product name against current approval lists before assigning a code here rather than to a standard transfusion code.
The most common mistake is coding a novel-sounding product under routine transfusion codes, or conversely, assuming any unfamiliar blood product automatically belongs in this family without checking that it actually holds New Technology status.
Commonly Confused With
This is easily confused with standard blood transfusion codes found in the Administration section. The difference comes down entirely to whether the specific product administered has been given New Technology recognition, not the clinical reason for the transfusion or the route used.